These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 16717032)

  • 1. Observations of alanine aminotransferase and aspartate aminotransferase in THRIVE studies treated orally with ximelagatran.
    Harenberg J; Jörg I; Weiss C
    Int J Toxicol; 2006; 25(3):165-9. PubMed ID: 16717032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ximelagatran for treatment and prophylaxis of recurrent events in deep vein thrombosis.
    Koscielny J; Kiesewetter H; Jörg I; Harenberg J
    Clin Appl Thromb Hemost; 2007 Jul; 13(3):299-307. PubMed ID: 17636192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of venous thromboembolism with the oral thrombin inhibitor, ximelagatran.
    Harenberg J; Ingrid J; Tivadar F
    Isr Med Assoc J; 2002 Nov; 4(11):1003-5. PubMed ID: 12489490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ximelagatran for the secondary prevention of venous thromboembolism: a complementary follow-up analysis of the THRIVE III study.
    Schulman S; Lundström T; Wålander K; Billing Clason S; Eriksson H
    Thromb Haemost; 2005 Oct; 94(4):820-4. PubMed ID: 16270637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran.
    Schulman S; Wåhlander K; Lundström T; Clason SB; Eriksson H;
    N Engl J Med; 2003 Oct; 349(18):1713-21. PubMed ID: 14585939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatran.
    Agnelli G; Eriksson BI; Cohen AT; Bergqvist D; Dahl OE; Lassen MR; Mouret P; Rosencher N; Andersson M; Bylock A; Jensen E; Boberg B;
    Thromb Res; 2009; 123(3):488-97. PubMed ID: 18485453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran.
    Eriksson H; Lundström T; Wåhlander K; Clason SB; Schulman S;
    Thromb Haemost; 2005 Sep; 94(3):522-7. PubMed ID: 16268466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial.
    Fiessinger JN; Huisman MV; Davidson BL; Bounameaux H; Francis CW; Eriksson H; Lundström T; Berkowitz SD; Nyström P; Thorsén M; Ginsberg JS;
    JAMA; 2005 Feb; 293(6):681-9. PubMed ID: 15701909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of recurrent venous thromboembolism of patients after termination of treatment with ximelagatran.
    Harenberg J; Jörg I; Weiss C
    Eur J Clin Pharmacol; 2006 Mar; 62(3):173-7. PubMed ID: 16416154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement.
    Francis CW; Berkowitz SD; Comp PC; Lieberman JR; Ginsberg JS; Paiement G; Peters GR; Roth AW; McElhattan J; Colwell CW;
    N Engl J Med; 2003 Oct; 349(18):1703-12. PubMed ID: 14585938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of the oral direct thrombin inhibitor ximelagatran: not yet the end of the warfarin era..
    Mohapatra R; Tran M; Gore JM; Spencer FA
    Am Heart J; 2005 Jul; 150(1):19-26. PubMed ID: 16084146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Melagatran and ximelagatran: new drug. No real simplification of anticoagulant therapy.
    Prescrire Int; 2005 Aug; 14(78):127-32. PubMed ID: 16106594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ximelagatran: oral direct thrombin inhibition as anticoagulant therapy in atrial fibrillation.
    Halperin JL
    J Am Coll Cardiol; 2005 Jan; 45(1):1-9. PubMed ID: 15629364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ximelagatran: a new oral anticoagulant.
    Hrebickova L; Nawarskas JJ; Anderson JR
    Heart Dis; 2003; 5(6):397-408. PubMed ID: 14633322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding.
    Douketis JD; Arneklev K; Goldhaber SZ; Spandorfer J; Halperin F; Horrow J
    Arch Intern Med; 2006 Apr; 166(8):853-9. PubMed ID: 16636210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ximelagatran.
    Choudhury A; Goyal D; Lip GY
    Drugs Today (Barc); 2006 Jan; 42(1):3-19. PubMed ID: 16511607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies.
    Diener HC;
    Cerebrovasc Dis; 2006; 21(4):279-93. PubMed ID: 16449807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention.
    Huisman MV; Bounameaux H
    Semin Vasc Med; 2005 Aug; 5(3):276-84. PubMed ID: 16123915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Ximelagatran for treatment of venous thromboembolism].
    Harenberg J; Fenyvesi T; Jörg I
    Hamostaseologie; 2002 Aug; 22(3):25-9. PubMed ID: 12215758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of recurrent venous thromboembolism or bleeding in relation to thrombophilic risk factors in patients receiving ximelagatran or placebo for long-term secondary prevention of venous thromboembolism.
    Wåhlander K; Eriksson H; Lundström T; Billing Clason S; Wall U; Nyström P; Wessman P; Schulman S;
    Br J Haematol; 2006 Apr; 133(1):68-77. PubMed ID: 16512831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.